• Non-coding RNA modifications of gastrointestinal cancer (Cancer Sci, 2024)

     

    In an academia-industry collaboration, Dr. Hara demonstrated the relationship between ncRNA modifications and cancer progression in gastrointestinal cancers, including colorectal and pancreatic cancers, and discussed enzyme inhibitors that target ncRNA modifications. By leveraging the novel perspective of ncRNA modifications, this aims to contribute to human health through improved diagnosis and treatment.

  • A novel target of chimeric antigen receptor T-cell therapy in solid tumor (Cancer Sci, 2024)

     

    Dr. Meng highlighted the significance of RNA-based chimeric antigen receptor T-cell (CAR-T) therapy against cancers, indicating that the challenges and future optimization directions of this treatment strategy are explored, providing new perspectives and strategies for ‘designer cell’ therapy in solid tumors.

  • Dr Hara’s paper (IBD bacterial flora) was highlighted in a cancer journal (Cancer Sci, 2024)

  • Tissue-resident memory T cells in gastrointestinal cancers: prognostic significance and therapeutic implications (Biomedicines, 2024)

     

    In collaboration with the Department of Gastroenterological Surgery at Osaka University Graduate School of Medicine, Japan, Dr. Sato has elucidated the pivotal role of tissue-resident memory T cells (Trm) in gastrointestinal cancers, paving the way for personalized and highly effective therapies.

     

  • RN7SL1 may be translated under oncogenic conditions (PNAS, 2024)

     

    As the international collaboration, Dr. Hara studied the significance of non-coding RNA, RN7SL1. RN7SL1 small Open Reading Frame (ORF) may be translated under special conditions such as those in cancer.

  • High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker (Cancer Sci, 2024)

     

    In a groundbreaking global partnership with Osaka University, Japan, Dr. Hara delved into the intricacies of RNA methylation within fresh specimens and organoid cultures derived from pancreatic cancer. Through meticulous research, Dr. Hara unveiled the activation of pivotal cell signaling pathways crucial in cancer metastasis. His findings shed light on the significance of m6A-activated TCEAL8 mRNA as a pioneering marker gene implicated in the malignant progression of pancreatic cancer.

  • Fat and proteolysis due to methionine, tryptophan, and niacin deficiency leads to alterations in gut microbiota and immune modulation in inflammatory bowel disease (Cancer Sci, 2024)

     

    In an international collaboration with Osaka University, Japan, Dr. Hara investigated the gut microbiome and immune modulation in inflammatory bowel disease (IBD), shedding light on the roles of amino acids in regulating one-carbon metabolism within this condition. His research suggests that controlling nutrient intake may offer a means to reset both gut microbiota composition and host gene expression, ultimately promoting a return to optimal health.

  • The significance of signal recognition particle 9: implications for pancreatic cancer prognosis and functionality (Int J Oncol, 2024)

     

    In the collaboration with Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Japan (Professors Eguchi and Doki), Dr. Sato studied the significance of signal recognition particle 9 (SRP9) in pancreatic cancer. The results of experiments indicated that SRP9, an ncRNA (RN7SL1)-binding protein, is involved in the signaling pathways of cancer progression and protein translation. The present study is opening an avenue to precise evaluation and therapeutic control of pancreatic cancer.

  • RNA methylation in inflammatory bowel disease (Cancer Sci, 2023)

     

    In the collaboration with Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Japan (Professors Eguchi and Doki), Dr. Ozato has focused on RNA methylation in inflammatory bowel disease (IBD), and emerged the significance in the process of inflammation, occurrence, and development of cancer. The information is expected to provide the potential applications of RNA modifications in the diagnosis and treatment of these diseases.

  • The link of mRNA and rRNA transcription as a novel therapeutic target for cancer (Biomedicines, 2023)

     

    In the collaboration with Chiba University, Japan, Dr. Kitamura has studied the novel function of linkage mechanism of mRNA and rRNA transcription, which contributes to the fundamental progress in cancer precision medicine.